James Foster Sells 75,000 Shares of Charles River Laboratories International (NYSE:CRL) Stock

Charles River Laboratories International, Inc. (NYSE:CRL) Director James Foster sold 75,000 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $225.00, for a total transaction of $16,875,000.00. Following the transaction, the director directly owned 31,596 shares of the company’s stock, valued at $7,109,100. This represents a 70.36% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Charles River Laboratories International Stock Up 1.0%

Shares of CRL traded up $2.34 during mid-day trading on Wednesday, reaching $229.13. The company had a trading volume of 1,086,088 shares, compared to its average volume of 933,448. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.03 and a current ratio of 1.36. The firm has a 50-day moving average price of $178.79 and a 200 day moving average price of $183.83. Charles River Laboratories International, Inc. has a 52 week low of $144.26 and a 52 week high of $236.62. The company has a market capitalization of $11.04 billion, a price-to-earnings ratio of -60.94, a price-to-earnings-growth ratio of 2.58 and a beta of 1.46.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share for the quarter, topping the consensus estimate of $1.96 by $0.10. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.The company had revenue of $995.83 million for the quarter, compared to the consensus estimate of $977.46 million. During the same quarter in the prior year, the business posted $2.34 EPS. The firm’s quarterly revenue was up 1.2% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. On average, sell-side analysts forecast that Charles River Laboratories International, Inc. will post 11.05 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on CRL. Morgan Stanley upgraded Charles River Laboratories International from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $185.00 to $220.00 in a report on Wednesday, June 17th. Robert W. Baird set a $213.00 price target on shares of Charles River Laboratories International in a research note on Friday, May 8th. Mizuho set a $192.00 price objective on shares of Charles River Laboratories International in a research report on Friday, May 8th. Weiss Ratings lowered shares of Charles River Laboratories International from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 16th. Finally, Evercore reaffirmed an “outperform” rating and issued a $220.00 target price on shares of Charles River Laboratories International in a report on Friday, May 8th. Twelve research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $215.88.

Hedge Funds Weigh In On Charles River Laboratories International

A number of hedge funds have recently bought and sold shares of the business. NewEdge Advisors LLC lifted its stake in Charles River Laboratories International by 1,119.5% during the 1st quarter. NewEdge Advisors LLC now owns 3,195 shares of the medical research company’s stock valued at $551,000 after acquiring an additional 2,933 shares during the period. Avidity Partners Management LP bought a new stake in shares of Charles River Laboratories International in the first quarter worth approximately $1,670,000. Glenmede Trust Co. NA grew its stake in shares of Charles River Laboratories International by 2.8% in the first quarter. Glenmede Trust Co. NA now owns 2,706 shares of the medical research company’s stock worth $467,000 after acquiring an additional 73 shares during the period. Bank of America Corp DE raised its holdings in shares of Charles River Laboratories International by 5.0% during the first quarter. Bank of America Corp DE now owns 1,135,027 shares of the medical research company’s stock valued at $195,792,000 after purchasing an additional 54,500 shares during the last quarter. Finally, Edgestream Partners L.P. purchased a new position in shares of Charles River Laboratories International during the first quarter valued at approximately $1,559,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.